The Mechanistic Core of Myalgic Encephalomyelitis

Abstract

Background. Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is characterized by post-exertional malaise (PEM), delayed symptom worsening, and failure to return to baseline despite rest. While numerous immune, metabolic, vascular, and neurological abnormalities have been described, a unifying explanation for persistence—as opposed to symptom expression alone—has remained unresolved.

Core mechanism. This document presents the GLA v2.8 mechanistic core: a closed, timing-first recovery-failure loop centered on cholesterol-organized control surfaces at the endoplasmic reticulum–mitochondria interface (ER–MAM). Persistence arises when recovery termination fails, not from primary oxidative injury, energy depletion, cytokine excess, or ongoing infection.

In this model, cholesterol-stiffened Caveolin-1 (Cav-1) microdomains fail to disengage after stress, preventing full ER–MAM calcium termination. Incomplete disengagement generates low-grade, recovery-phase reactive oxygen species (ROS) that chemically convert cholesterol into bioactive oxysterols. These oxysterols actively suppress ER lipid-reset programs, bias cholesterol retention, and make membrane disengagement progressively more expensive. Termination failure therefore becomes chemically enforced, closing a self-reinforcing ROS–cholesterol–ER–MAM loop.

From persistence to PEM. As termination cost rises, adaptive membrane braking mechanisms such as SMPDL3B anchoring become unsafe and are lost or withheld as fail-safes. Persistent calcium signaling quietly elevates resting sodium, narrowing calcium safety margins without reversing core ion pumps. When physiological demand increases, localized recovery-phase calcium overload occurs, producing post-exertional malaise as a contained, tissue-level collapse rather than an exertion-time failure.

Integration. The framework integrates genetic and endocrine termination-robustness bias, Cav-1 control-surface persistence, ER–MAM calcium non-termination, oxysterol-mediated cholesterol trapping, skeletal muscle as the primary PEM execution surface, and downstream vascular, redox, immune, and extracellular-vesicle amplifiers that shape severity but do not maintain the disease.

Scope. This is a mechanistic synthesis, not a diagnostic or treatment guide. It does not require ongoing infection, cytokine storms, or psychogenic causation, and it does not claim a single initiating trigger for all cases. Its purpose is to explain how recovery becomes chemically prevented from finishing, why PEM is delayed and cumulative, and why ME/CFS can persist even after the original stressor has resolved.

Introduction — The Closed ROS–Cholesterol–ER–MAM Loop

This mechanistic chain extends the vascular–mitochondrial model of post-exertional malaise (PEM) proposed by Wirth and Scheibenbogen, completing it into a closed, self-reinforcing recovery-failure loop [18]. While the Wirth–Scheibenbogen model correctly identifies impaired oxygen delivery, sodium–calcium handling, and mitochondrial stress as central to PEM expression, the v2.8 additions presented here specify why recovery repeatedly fails to terminate and how mild or resolved stress is converted into persistent pathology via cholesterol-organized control surfaces and chemically enforced suppression of recovery programs [18].

ME/CFS is proposed to arise from a failure of recovery termination, not from primary oxidative injury, inflammation, or energy depletion. Under healthy conditions, cholesterol-organized Caveolin-1 (Cav-1) control platforms transiently assemble to coordinate mechanosensing, catecholamine signaling, calcium routing, and nitric-oxide timing, then disassemble as recovery completes [6]. Under sustained or repeated stress, these platforms can remain engaged beyond their normal recovery window, increasing signaling gain, membrane rigidity, and the energetic cost of disengagement [6].

Genetic background does not directly cause this failure but biases termination robustness. Variants affecting cholesterol routing and efflux, oxysterol handling, and calcium signal decay reduce the probability that Cav-1 platforms cleanly disengage once engaged [1] [2]. As recovery termination becomes delayed, maintaining SMPDL3B anchoring within rigid, cholesterol-stabilized microdomains becomes structurally costly. The system resolves this mismatch by sacrificing SMPDL3B, removing a raft-localized brake on receptor gain and PLC/IP₃ permissiveness [6]. Control logic inverts: signaling platforms persist, while termination probability drops.

Once termination is unreliable, recovery-phase signaling shifts from high-amplitude responses to low-amplitude, long-duration persistence. ER–mitochondria (ER–MAM) disengagement becomes incomplete, calcium microdomains decay slowly, and mild but persistent ROS is generated during failed recovery [8] [9]. This ROS does not initiate disease; instead, it chemically transforms cholesterol into bioactive oxysterols that actively suppress ER lipid-reset programs, bias cholesterol retention, and stabilize Cav-1 microdomains [10] [11] [12] [13]. At this point, membrane stiffness and termination cost are no longer merely mechanical—they are chemically enforced. The result is a closed loop in which termination failure generates ROS, ROS generates oxysterols, and oxysterols prevent recovery from finishing.

Within this closed ROS–cholesterol–ER–MAM loop, several biological adaptations emerge to preserve viability when termination cannot be achieved. One of these is the loss or withholding of SMPDL3B, which functions as a local fail-safe, not a disease driver. This adaptation prevents catastrophic calcium overload at the cost of signaling precision and recovery reliability [6].

Once oxysterol-reinforced membrane states are established, disease identity is fixed. Delayed PEM becomes possible, phenotype selection (shedding versus deficient) follows membrane rebuild constraints, and downstream persistence mechanisms—including adipose duration memory and Maintenance Lock Layer engagement—are recruited. Continued infection, inflammation, or primary mitochondrial collapse are not required [18]. From this point onward, genetics primarily shape severity, expression, and reversibility rather than initiation [1] [2], with endocrine and epigenetic modifiers shaping vulnerability [3] [4] [24]. The illness is sustained because recovery is chemically prevented from finishing, not because injury or activation persists.

Citation map (this section). References used: [1], [2], [3], [4], [6], [8], [9], [10], [11], [12], [13], [18], [24].

1. Termination Robustness & Vulnerable Baseline

2. Control Surfaces & Termination Architecture

3. ER–MAM Calcium Non-Termination

3.2 Mild ROS Is Generated During Failed Recovery

Incomplete ER–MAM disengagement does not produce acute injury or inflammatory collapse. Instead, it generates low-grade, chronic reactive oxygen species (ROS) during the recovery phase, reflecting persistent microdomain stress rather than overt pathology [8] [9].

When ER–MAM contacts remain partially engaged, calcium signaling continues at low amplitude, increasing basal metabolic and redox load. This produces ROS through several converging mechanisms:

• Mitochondrial Ca²⁺ inefficiency: prolonged microdomain calcium exposure reduces coupling efficiency and increases electron leak [9].
• ER stress–linked ROS: incomplete SERCA reset and ongoing protein-folding demand generate redox pressure within the ER [8].
• NADPH oxidase activation: persistent signaling at membrane control surfaces promotes localized ROS production without systemic inflammation [21].

Importantly, ROS levels in this state are modest. They are insufficient to cause widespread oxidative damage, cytokine storms, or acute tissue injury. Instead, they are precisely in the range required to alter lipid chemistry, particularly cholesterol within ordered membrane microdomains [8] [9].

This framing aligns with observations that redox imbalance is a consistent downstream signature in ME/CFS and Long COVID, while not serving as a primary initiating lesion [21]. ROS here functions as a chemical consequence of failed recovery, not as an upstream driver.

In brief. Incomplete ER–MAM disengagement generates modest, chronic ROS that alters lipid chemistry without causing acute injury.

Citation map (this section). References used: [8], [9], [21].

3.3 ROS Chemically Traps Cholesterol and Initiates the Persistence Loop

During failed recovery, low-grade reactive oxygen species (ROS) generated at ER–mitochondria contact sites do not merely increase membrane rigidity. Instead, ROS chemically transforms cholesterol into bioactive oxysterols, particularly within Caveolin-1 (Cav-1)–rich microdomains and ER–MAMs [11] [12]. These oxysterols act as active lipid mediators rather than inert damage products, initiating a qualitative shift in system behavior.

Oxysterol formation triggers several reinforcing effects simultaneously:

• INSIG binding and SREBP suppression: oxysterols bind ER-resident sensing machinery, preventing SCAP–SREBP-2 transport to the Golgi and blocking ER lipid-reset programs from re-engaging [10] [11].
• ACAT bias toward esterification: cholesterol is preferentially esterified, favoring retention over redistribution and repair [11] [12].
• Reduced efflux and increased Cav-1 residency: cholesterol remains localized within ordered microdomains, prolonging Cav-1 platform lifetime and signaling gain [13].

As a result, cholesterol becomes functionally retained rather than overproduced. Cav-1 microdomains transition from transient control platforms into persistent, high-gain signaling surfaces. At this point, membrane stiffness is no longer merely mechanically costly—it is chemically enforced [10] [11].

The ER-anchored persistence loop.
Failed recovery generates ROS → ROS generates oxysterols → oxysterols suppress ER lipid reset and enforce cholesterol retention → membrane stiffness persists → recovery fails again.

From this step onward, recovery is no longer limited by time, substrate availability, or effort. Instead, ER reset programs are actively vetoed, preventing return to a low-stress baseline even in the absence of further insult [10] [13].

Importantly, standard blood lipid markers (HDL, LDL, triglycerides) reflect systemic lipid transport and clearance and do not measure this membrane-localized cholesterol state. Circulating lipid alterations may appear downstream, but they are not equivalent to—and cannot resolve—oxysterol-reinforced microdomain persistence [20]. Consequently, lipid-lowering strategies targeting blood cholesterol do not address the core control failure described here.

Mechanistic note.
Oxysterols enforce persistence by binding INSIG at the endoplasmic reticulum, preventing SCAP–SREBP-2 trafficking to the Golgi and thereby blocking lipid synthesis and membrane reset programs. This constitutes a chemical veto on recovery rather than a gradual slowdown: membrane renewal cannot be authorized until oxysterol pressure falls and ER control logic releases this block [10] [11].

In brief. Recovery-phase ROS converts cholesterol into bioactive oxysterols that chemically suppress ER lipid reset, locking Cav-1 microdomains into a stiff, high-gain configuration and initiating the self-sustaining persistence loop.

Citation map (this section). References used: [10], [11], [12], [13], [20].

4. Phase Transition: When Persistence Becomes Possible

Phase Transition Note — Where Persistence Becomes Possible

At this point in the mechanistic chain, the system crosses a critical threshold. Once cholesterol is chemically trapped within Cav-1–organized microdomains and membrane stiffness rises beyond a recoverable range, normal recovery termination is no longer reliably achievable—even in the absence of further stress [10] [11].

The removal or withholding of SMPDL3B marks this transition. Although protective, this adaptation signals that membrane braking mechanisms can no longer be safely maintained under the prevailing lipid and redox conditions. From here onward, recovery attempts proceed with reduced precision and limited headroom [7] [25].

This transition is pivotal. Post-exertional malaise now becomes possible, and the illness can sustain itself through the closed ROS–cholesterol trapping loop alone. Further stress is no longer required to maintain vulnerability; it merely determines how often and how severely the system is forced into containment [10] [11].

From this point forward, the mechanisms described by Wirth and Scheibenbogen—elevated resting sodium, reduced calcium safety margins, and regional NCX reversal during recovery—are expressed as downstream physiological consequences of upstream control-surface failure, not as initiating causes [18].

Canonical transition statement.
Once cholesterol trapping renders membrane braking unsafe, ME/CFS becomes self-sustaining: PEM is now possible, and downstream ionic and vascular failures emerge as consequences of lost termination headroom.

Citation map (this section). References used: [7], [10], [11], [18], [25].

5. Ionic Headroom Collapse & PEM Execution

5.2 The Sodium Pump Becomes Fragile, Not Reversed

As resting sodium rises during persistent recovery-phase non-termination, the failure mode that emerges is not sodium–potassium pump reversal or global ionic collapse. Instead, the system enters a fragile, low-headroom state in which normal homeostasis is preserved but increasingly expensive to maintain [14] [18].

Elevated baseline Na⁺ alters ionic economics in several predictable ways:

• ATP cost of homeostasis rises, as the Na⁺/K⁺-ATPase must work closer to its maximal throughput to maintain resting gradients [18].
• NCX buffering capacity shrinks, because reduced transmembrane Na⁺ gradients narrow the operational window for calcium extrusion [14].
• The system retains viability but loses reserve, leaving little margin for additional demand during exertion or stress [18].

Structural and functional studies of the sodium–calcium exchanger (NCX) support this framing: exchanger behavior depends on local ion gradients and membrane potential, such that elevated resting sodium reduces calcium-buffering headroom and permits conditional, regional reversal under stress—without implying global pump failure [14].

This logic aligns with the Wirth–Scheibenbogen framework, in which ME/CFS physiology remains viable at rest but becomes disproportionately crash-prone because buffering margins are already consumed by unresolved recovery work [18].

In brief. Elevated basal sodium narrows the calcium safety margin, leaving the system viable but extremely vulnerable to collapse when demand increases.

Citation map (this section). References used: [14], [18].

5.3 Exertion or Stress Triggers PEM (Headroom Collapse)

When physiological demand increases—whether physical, cognitive, shear-related, or emotional— the already fragile ionic system is pushed beyond its remaining buffering headroom. Because resting sodium is elevated and calcium safety margins are narrowed, additional load disproportionately stresses recovery-phase control rather than exertion-time capacity [14] [18].

As demand rises, several coupled effects occur:

• Na⁺ load rises further, consuming the remaining transmembrane gradient and pushing exchanger dynamics toward instability [15].
• SERCA demand increases, as calcium cycling intensifies during attempted recovery under load [18].
• NCX reverses regionally, not globally, because reduced headroom permits localized exchanger reversal without whole-cell pump failure [14] [18].

These dynamics do not produce uniform cellular collapse. Instead, they generate localized calcium overload in vulnerable regions, leading to:

• Focal Ca²⁺ overload within stressed microdomains [14].
• Localized mitochondrial failure in affected fibers or endothelial segments [18].
• Regional necrosis with adjacent regeneration, consistent with biopsy-based observations rather than deconditioning [16] [17].

Critically, this process unfolds during the recovery phase, not at the moment of exertion. Exertion reveals the reduced headroom, but tissue injury and symptom amplification emerge later as recovery attempts fail to complete [16] [17].

Key framing.
Post-exertional malaise is not an exertion-time energy failure. It is a recovery-phase containment response that limits damage when demand exceeds reduced ionic and metabolic headroom.

In brief. When demand exceeds reduced headroom, localized calcium overload occurs during recovery, producing PEM as a controlled, tissue-level collapse.

Citation map (this section). References used: [14], [15], [16], [17], [18].

5.4 PEM Generates Larger ROS Bursts Locally

Once post-exertional malaise (PEM) is triggered, the system does not enter a uniform, whole-body oxidative crisis. Instead, the defining feature is localized recovery-phase injury, where stressed regions generate higher ROS transients while the overall organism remains viable.

During PEM, several reinforcing processes occur in the affected regions:

• Ca²⁺ overload amplifies ROS production, increasing lipid-oxidation pressure precisely where control surfaces are already vulnerable [11] [12].
• Damaged regions release oxidized lipids and extracellular vesicles (EVs), exporting recovery-phase stress signals beyond the local tissue compartment [23].
• Mitochondrial and ER stress intensify transiently, increasing redox load and extending the recovery work required to return toward baseline [21] [23].

The critical point is that ROS is now higher, but still spatially contained: the organism maintains global viability, while localized regions undergo disproportionate stress and repair. This preserves the “quiet persistence” pattern—no cytokine storm required—while deepening lipid oxidation chemistry at the exact sites that govern termination cost [21].

In brief. Recovery-phase injury amplifies ROS in affected regions, deepening lipid oxidation without systemic collapse.

Citation map (this section). References used: [11], [12], [21], [23].

5.5 Larger ROS Deepens Cholesterol Trapping

The elevated, localized ROS generated during post-exertional malaise does not dissipate harmlessly. Instead, it feeds directly back into the core persistence mechanism by further stabilizing cholesterol retention at membrane control surfaces.

As ROS levels rise in affected regions during PEM, several reinforcing effects occur:

• Cholesterol is further oxidized, increasing the local concentration of bioactive oxysterols within Cav-1–rich microdomains [11] [12].
• ACAT bias toward esterification strengthens, favoring cholesterol retention and storage over redistribution and membrane renewal [10] [11].
• Cav-1 microdomain persistence increases, prolonging signaling platform lifetime and further raising termination cost [13].

The consequence is a stepwise increase in membrane rigidity after each crash. Cholesterol trapping is no longer merely maintained—it is deepened. Each PEM episode therefore leaves the system in a slightly stiffer, higher-gain configuration than before, even after symptoms partially subside.

Importantly, this process reflects a state problem rather than excess cholesterol production. ER-level cholesterol sensing and non-vesicular transport logic determine whether membranes can be renewed, and elevated oxysterol pressure keeps reset programs suppressed despite adequate substrate availability [10] [13].

In brief. Higher ROS further stabilizes cholesterol retention, ensuring that the next recovery attempt fails sooner and at lower levels of demand.

Citation map (this section). References used: [10], [11], [12], [13].

5.6 ER–MAM Non-Closure Is Reinforced

As membrane stiffness increases following repeated cholesterol trapping, the difficulty of completing ER–MAM disengagement rises further. Reinforced rigidity feeds back directly into contact-site dynamics and calcium termination geometry, degrading the reliability of recovery completion [8] [9].

With stiffer membranes, several compounding effects emerge:

• ER–MAM disengagement becomes harder, as contact sites remain partially engaged for longer portions of the recovery window [8].
• Ca²⁺ tails lengthen, because microdomain duration and geometry favor slow decay rather than clean termination [9].
• PLC/IP₃ retry probability rises, as incomplete termination increases the likelihood that signaling attempts re-initiate before recovery has closed [9].

The consequence is not immediate catastrophe, but a progressive erosion of termination reliability. Each cycle of failed recovery leaves calcium signaling active for longer, increasing basal load and making subsequent recovery attempts even less likely to finish cleanly—without requiring any new initiating insult [9].

In brief. Each cycle lengthens calcium tails and increases retry probability, making recovery completion progressively less likely.

Citation map (this section). References used: [8], [9].

5.7 The Loop Closes and Escalates

At this stage, the system returns to “baseline” after each episode with a changed internal configuration. Baseline is preserved in the sense of viability, but it is progressively less resilient. After each cycle, the system tends to show:

• Higher cholesterol rigidity (more persistent, less flexible control surfaces) [10] [11] [12] [13].
• Higher resting Na⁺, reflecting persistent recovery-phase ionic work [15].
• Lower Ca²⁺ safety margin, because reduced Na⁺ gradients narrow NCX buffering headroom [14].
• Greater PEM sensitivity, because demand now reaches collapse thresholds sooner [14] [15].

Each cycle therefore lowers the threshold for the next crash. The illness becomes self-reinforcing because the loop is closed:

ROS maintains cholesterol retention → cholesterol stiffens membranes → termination fails → ionic headroom shrinks → PEM occurs → ROS increases → cholesterol trapping deepens.

Mechanistically, this is an ER-centered state lock rather than a simple “high cholesterol” condition: cholesterol retention → ER–MAM non-termination → ROS → oxysterols → ER reset veto → more retention [10] [11] [12] [13].

In parallel, sodium elevation and NCX margin narrowing explain why PEM thresholds drop with repeated cycles: as resting Na⁺ rises, the buffering window for Ca²⁺ handling shrinks, making regional reversal and localized overload more likely under smaller loads [14] [15].

Genetic heterogeneity helps explain why thresholds and recovery bandwidth vary between individuals: variants affecting lipid routing, sterol handling, and metabolic resilience bias termination robustness and set different baseline distances to the same failure boundary [1] [2].

In brief. Repeated cycles lower the threshold for PEM, locking the system into a self-reinforcing recovery-failure state.

Citation map (this section). References used: [1], [2], [10], [11], [12], [13], [14], [15].

6. Downstream Amplifiers (Expression, Not Persistence)

Why These Processes Amplify Symptoms but Do Not Sustain the Disease

The processes listed above function as amplifiers and spreaders, not as engines. They shape how severe, how widespread, and how variable symptoms are, but they cannot by themselves keep the illness going once stress is removed. What makes ME/CFS unusually persistent is that these amplifiers operate within narrow recovery boundaries set upstream by cholesterol-mediated termination failure and ER-level reset suppression [10] [11].

When recovery termination is unreliable, even modest physiological noise becomes consequential. Shear stress and nitric-oxide mistiming exaggerate vascular and cognitive symptoms; autonomic instability amplifies heart rate and blood pressure variability; immune surveillance sustains a low-grade “do not disengage” signal without cytokine storms; and mitochondrial stress signaling reflects local overload rather than global failure. RBC damage and extracellular vesicle release further spread stress signals systemically, while adipose duration memory extends the temporal footprint of prior stress. Each of these mechanisms broadens expression but still depends on the same upstream constraint: the inability of membranes and ER–MAM interfaces to fully reset [10] [11].

This is why ME/CFS has strong recovery boundaries. Once the cholesterol–ER–MAM loop is established, recovery is not limited by willingness, effort, or even substrate availability, but by termination cost. Crossing back into health requires multiple consecutive recovery cycles that fully close—a rare event when amplifiers continually re-inject noise into an already fragile system. As a result, improvement is slow, non-linear, and easily reversed, while relapse can occur with disproportionately small stressors.

Genetic modifiers help explain why patients differ in threshold distance and buffer size. These variants can increase the visibility and severity of amplifier effects—by lowering thresholds or shrinking buffering capacity—without changing the core persistence engine [1] [2].

Systems-level multi-omics modeling can identify reproducible disease states and subgroups, but it should be treated as descriptive and predictive rather than causal proof of any single mechanism [24].

Bottom line.
These mechanisms widen and prolong symptoms by injecting noise into recovery, but only cholesterol-mediated termination failure prevents recovery from finishing, which is why ME/CFS is persistent rather than merely reactive [10] [11].

Citation map (this section). References used: [1], [2], [10], [11], [24].

Why Blocking Adaptations Is Dangerous

Within the closed ROS–cholesterol–ER–MAM loop, SMPDL3B functions as a protective fail-safe, not as a pathological driver. Its loss—whether through active shedding or strategic withholding—represents a selected response to cholesterol-stiffened control surfaces, designed to prevent catastrophic calcium overload and global cellular injury when recovery cannot terminate cleanly [7].

When cholesterol-organized Caveolin-1 (Cav-1) microdomains become overly rigid, maintaining SMPDL3B anchoring becomes structurally and energetically costly. In this context, sacrificing SMPDL3B lowers membrane order and termination cost, allowing the system to survive persistent recovery-phase stress at the expense of signaling precision and long-term efficiency. This is why SMPDL3B loss often coincides with heightened signaling gain, delayed termination, and post-exertional malaise—but does not itself define the disease [7] [25].

Crucially, treating ME/CFS does not require preventing SMPDL3B shedding or forcibly increasing GPI anchoring. Both shedding-dominant and deficient-dominant patterns represent adaptive resolution strategies under conditions of membrane rigidity and maintenance constraint. Attempting to suppress these strategies without correcting the upstream lipid state risks destabilizing membranes further and increasing the likelihood of uncontrolled calcium signaling [7] [25] [10] [11].

Recovery instead requires restoration of cholesterol homeostasis at membrane control surfaces. As cholesterol redistributes normally and membrane stiffness decreases, termination becomes energetically inexpensive again. Under these conditions:

• Cav-1 platforms regain the ability to disengage after stress.
• ER–MAM calcium signaling can fully terminate.
• ROS production decays naturally rather than being continuously regenerated.
• SMPDL3B anchoring becomes safe and sustainable without forcing.

As long as post-exertional malaise is minimized and recovery is allowed to fully close repeatedly, this process can unfold gradually over time. Shedding diminishes on its own, deficient systems re-enable anchoring when safe, and the closed loop loosens—not because adaptations were blocked, but because they are no longer needed.

Key clarification.
SMPDL3B loss is not the cause of ME/CFS persistence; it is part of the system’s protection against catastrophic failure. The disease persists because cholesterol-stiffened membranes make termination expensive. Recovery occurs when termination becomes cheap again.

Citation map (this section). References used: [7], [10], [11], [25].

The Primary Constraint on Recovery Termination

Within this framework, persistence in ME/CFS is not maintained by ongoing injury or by failure of individual components, but by a chemical constraint on recovery termination centered at the endoplasmic reticulum. During repeated recovery-phase non-closure, low-grade ROS generated at ER–mitochondria interfaces produces bioactive oxysterols that actively suppress ER lipid-reset programs and bias cholesterol retention at membrane control surfaces [10] [11] [12].

This ER-anchored ROS–oxysterol loop does not function as a pathological “driver” in the conventional sense. Rather, it acts as a state-dependent veto that prevents exit from the recovery phase once established. As long as oxysterol pressure persists, ER control logic suppresses membrane renewal and termination remains energetically expensive [10] [13].

Critically, this constraint cannot be bypassed by increasing energy supply, correcting individual signaling nodes, or suppressing downstream adaptations. As long as oxysterol pressure remains, membrane remodeling is chemically vetoed at the ER, recovery cannot reliably finish, and termination cost stays high. This explains why improvement is slow and fragile, why relapse can occur after minimal stress, and why many plausible interventions fail despite transient benefit [11] [12].

Non-vesicular cholesterol transport and ER-centric sterol sensing further support this framing: the ER governs the accessible cholesterol pool that determines whole-cell membrane renewal state. Small, persistent changes in ER sterol chemistry therefore control whether recovery can terminate at all [13].

Rate-limiting constraint.
This pressure point is best understood as a rate-limiting condition on recovery, not as a molecular target. Meaningful improvement requires prolonged conditions under which oxysterol generation falls, existing oxysterols are cleared or neutralized, and ER lipid reset programs are permitted to resume over multiple uninterrupted recovery cycles.

Citation map (this section). References used: [10], [11], [12], [13].

Clinical Implications: What This Model Does — and Does Not — Justify

What this model does justify

1. Prioritizing protection of recovery over increasing capacity.
   The central therapeutic goal implied by this framework is to reduce the frequency and depth of recovery-phase non-closure. Preventing repeated engagement of the ROS–cholesterol–ER–MAM loop lowers cumulative damage risk and preserves long-term viability. Interventions that protect recovery integrity therefore take precedence over those that increase output, stimulation, or metabolic throughput [10] [11].
2. Interpreting pacing as a biological intervention, not a behavioral strategy.
   Within this model, pacing is not symptom management or deconditioning avoidance. It is a mechanistically grounded intervention that reduces repeated loop engagement, limits ROS-driven cholesterol trapping, and allows recovery termination to complete. Respecting post-exertional limits is therefore a form of cellular protection, not patient compliance [16] [17].
3. Understanding post-exertional malaise as containment, not failure.
   Post-exertional malaise represents a controlled, localized expression of stress that prevents global collapse when recovery cannot terminate cleanly. The goal of care is not to “push through” PEM, but to reduce how often and how deeply this containment mechanism must be invoked [18].

What this model does not justify

1. Forcing recovery through stimulation, activation, or graded stress.
   Because the core failure lies in termination rather than capacity, increasing demand in the absence of reliable recovery closure predictably worsens the condition. Strategies that rely on retraining tolerance, pushing thresholds, or overriding symptoms are biologically mismatched to the failure mode described here [14] [15] [18].
2. Expecting antioxidant or single-pathway interventions to break the loop.
   Reactive oxygen species in this model are sustained by termination failure, not by primary oxidative pathology. Suppressing ROS without restoring recovery completion may reduce markers or symptoms transiently, but does not resolve the underlying loop and may permit continued retry behavior [10] [11].
3. Interpreting symptom-quiet periods as biological reset.
   Periods of reduced symptoms do not necessarily reflect restoration of termination robustness. Without repeated, fully completed recovery cycles, vulnerability to re-engagement remains high. Care decisions should therefore be based on stability over time, not isolated improvements [10] [11].

Clinical framing.
Persistence in ME/CFS is not overcome by capacity pushing or by isolated downstream fixes. It reflects a termination failure enforced by ER-level chemistry. Ion-margin collapse explains why exertion worsens disease even when “energy” appears available, and muscle pathology confirms that recovery-phase injury amplification is real—validating pacing as biological protection rather than behavioral accommodation [14] [15] [16] [17] [18].

Citation map (this section). References used: [10], [11], [14], [15], [16], [17], [18].

Clinical Framing to Carry Forward

In this framework, ME/CFS is not a disease of insufficient effort, insufficient repair, or insufficient stimulation. It is a condition in which recovery cannot reliably finish, and the system adopts protective strategies to avoid catastrophic injury. Effective patient care therefore emphasizes harm minimization, recovery protection, and long-term stability, rather than optimization or acceleration

This model supports a cautious, patient-centered approach in which interventions are evaluated primarily by whether they reduce recovery interruption and lower re-engagement of post-exertional pathology, rather than by whether they transiently improve performance or laboratory measures

Conclusion

This work reframes ME/CFS as a disorder sustained by failure of recovery termination, not by persistent injury, inflammation, infection, or energy depletion. The closed ROS–cholesterol–ER–MAM loop described here identifies a single, causally upstream mechanism by which otherwise normal stress responses become self-reinforcing: cholesterol-stiffened control surfaces raise the cost of disengagement, recovery fails to finish, ER-anchored recovery-phase ROS generates bioactive oxysterols, and these chemically enforce cholesterol retention and termination failure over time [8] [9] [10] [11] [12] [13].

Within this framework, post-exertional malaise is not an anomaly or exaggeration of fatigue, but a contained expression of stress that protects the organism from catastrophic collapse when termination cannot be achieved. Likewise, biological adaptations such as SMPDL3B shedding or withholding are not pathological errors, but fail-safe strategies selected to preserve viability under chemically enforced membrane rigidity. These adaptations explain clinical heterogeneity and progression without fragmenting disease identity or invoking multiple primary causes [8] [9] [11] [12].

Importantly, this model resolves long-standing paradoxes in ME/CFS research. It explains why laboratory measures can appear normal despite profound disability, why symptom-quiet periods do not guarantee biological reset, why cognitive or emotional stress can provoke delayed PEM, and why interventions that increase demand or stimulation so often worsen outcomes despite appearing rational. The common thread is not insufficient capacity, but inability to reliably close recovery under an ER-level chemical constraint [14] [15] [16] [17].

The central implication is therefore conservative but clarifying: ME/CFS persists because recovery is chemically prevented from finishing. Durable improvement requires restoration of conditions under which termination becomes energetically inexpensive again— allowing ER lipid-reset programs to resume, cholesterol to redistribute, ER–MAM disengagement to complete, calcium signaling to resolve, and oxysterol pressure and ROS to decay over time. This process cannot be forced, accelerated, or bypassed by targeting downstream adaptations or single molecular components [10] [11] [12] [13].

By placing recovery termination—and its ER-anchored chemical constraint—at the center of disease maintenance, this framework prioritizes patient safety, validates lived experience, and provides a coherent lens through which diverse findings can be integrated without overreach. It does not offer a shortcut to cure, but it does offer a stable foundation: one that replaces blame with biology, complexity with hierarchy, and urgency with precision. Genetic heterogeneity further explains why thresholds and reversibility vary between patients without altering the shared persistence engine [1] [2].

Final framing.
In ME/CFS, recovery is not absent—it is unfinished. Understanding why recovery fails to close, and why that failure is chemically enforced, is the first step toward ensuring it can, safely and sustainably, do so again.

Citation map (this section). References used: [1], [2], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17].

References (APA 7th ed.) — GLA v2.8 Core Mechanistic Chain

Re-ordered to match the sequence of the Closed ROS–Cholesterol–ER–MAM–PEM Loop.

I. Upstream Vulnerability & Threshold Bias

(Why termination robustness varies; not persistence engines)

1. Sardell, J. M., Das, S., Pearson, M., Kolobkov, D., Malinowski, A. R., Fullwood, L. M., … Gardner, S. (2025). Identification of novel reproducible combinatorial genetic risk factors for myalgic encephalomyelitis in the DecodeME patient cohort and commonalities with Long COVID.
   https://doi.org/10.64898/2025.12.01.25341362

   Role: Polygenic threshold bias; explains heterogeneity and susceptibility to termination failure.

2. Huang, K., Muneeb, M., Thomas, N., Schneider-Futschik, E. K., Gooley, P. R., Ascher, D. B., & Armstrong, C. W. (2026). Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK Biobank. iScience, 29(1), 110577.
   Link

   Role: Genetic modifiers of lipid routing, oxysterol sensitivity, and Ca²⁺ timing.

3. de Vega, W. C., Herrera, S., Vernon, S. D., & McGowan, P. O. (2017). Epigenetic modifications and glucocorticoid sensitivity in ME/CFS. BMC Medical Genomics, 10(1), 11.
   https://doi.org/10.1186/s12920-017-0248-3

   Role: Epigenetically encoded glucocorticoid duration bias; stress tails without hypercortisolemia.

II. Glucocorticoid Duration Bias & Adipose Vulnerability

(Permissive background state; reversible alone)

4. Tholen, S., Patel, R., Agas, A., Kovary, K. M., Rabiee, A., Nicholls, H. T., et al. (2022). Flattening of circadian glucocorticoid oscillations drives acute hyperinsulinemia and adipocyte hypertrophy. Cell Reports, 39(13), 111018.
   https://doi.org/10.1016/j.celrep.2022.111018

   Role: GC duration bias creates a reversible metabolic “alert state.”

5. Hepler, C., & Gupta, R. K. (2017). The expanding problem of adipose depot remodeling and postnatal adipocyte progenitor recruitment. Molecular and Cellular Endocrinology, 445, 95–108.
   https://doi.org/10.1016/j.mce.2016.10.011

   Role: Adipose as a slow, depot-specific duration-memory amplifier.

III. Control Surfaces & Termination Architecture

(Where recovery must disengage)

6. Parton, R. G., & del Pozo, M. A. (2013). Caveolae as plasma membrane sensors, protectors and organizers. Nature Reviews Molecular Cell Biology, 14(2), 98–112.
   https://doi.org/10.1038/nrm3512

   Role: Cav-1 platforms must disassemble after stress; persistence is pathological.

7. Heinz, L. X., Baumann, C. L., Köberlin, M. S., et al. (2015). The lipid-modifying enzyme SMPDL3B negatively regulates innate immunity. Cell Reports, 11(12), 1919–1928.
   https://doi.org/10.1016/j.celrep.2015.05.006

   Role: SMPDL3B defined as a membrane termination brake, not an immune defect.

IV. ER–MAM Structure, Calcium Termination, and ROS Generation

(Failure here creates persistence conditions)

8. Liu, Y., Mao, Z. H., Huang, J., et al. (2025). Mitochondria-associated endoplasmic reticulum membranes in human health and diseases. MedComm, 6(7), e70259.
   https://doi.org/10.1002/mco2.70259

   Role: ER–MAM anchor; 40–60% cholesterol enrichment; termination plasticity.

9. Modesti, L., Danese, A., Vitto, A. M., et al. (2021). Mitochondrial Ca²⁺ signaling in health, disease and therapy. Cells, 10(6), 1317.
   https://doi.org/10.3390/cells10061317

   Role: Ca²⁺ duration and microdomain geometry determine pathology, not overload.

V. Cholesterol Routing, Oxysterols, and Chemical Persistence

(The core persistence engine)

10. Luo, J., Yang, H., & Song, B.-L. (2020). Mechanisms and regulation of cholesterol homeostasis. Nature Reviews Molecular Cell Biology, 21(4), 225–245.
    https://doi.org/10.1038/s41580-019-0190-7
11. Griffiths, W. J., & Wang, Y. (2020). Oxysterols as lipid mediators. Prostaglandins, Leukotrienes and Essential Fatty Acids, 147, 106381.
    https://doi.org/10.1016/j.prostaglandins.2019.106381
12. Ferrari, A., & Tontonoz, P. (2025). Nonvesicular cholesterol transport in physiology. Journal of Clinical Investigation, 135(6), e188127.
    https://doi.org/10.1172/JCI188127

    Role: ER-centric cholesterol accessibility and retention logic.

VI–XI. Downstream Execution, Amplifiers, and State Signatures

Includes ionic headroom collapse, skeletal muscle PEM execution, vascular timing, redox amplification, extracellular vesicles, AI-derived state signatures, and SMPDL3B as a state-dependent biomarker. These shape expression and severity but do not maintain the core loop.

VI. Ionic Headroom Collapse & PEM Execution

(How persistence becomes symptomatic)

14. Xue, J., Zeng, W., Han, Y., et al. (2023). Structural mechanisms of the human cardiac sodium–calcium exchanger NCX1. Nature Communications, 14, 6181.
    https://doi.org/10.1038/s41467-023-41885-4

    Role: Structural basis for sodium–calcium coupling and reduced buffering headroom under elevated resting Na⁺.

15. Petter, E., Scheibenbogen, C., Linz, P., et al. (2022). Muscle sodium content in patients with ME/CFS. Journal of Translational Medicine, 20, 580.
    https://doi.org/10.1186/s12967-022-03616-z

    Role: In vivo evidence of elevated skeletal muscle sodium consistent with reduced calcium safety margins.

VII. Skeletal Muscle as Primary PEM Execution Surface

16. Charlton, B. T., Slaghekke, A., Appelman, B., et al. (2025). Skeletal muscle properties in long COVID and ME/CFS differ from those induced by bed rest. medRxiv.
    https://doi.org/10.1101/2025.01.12.23284473

    Role: Direct evidence that PEM reflects true muscle pathology and delayed injury, not deconditioning.

17. Scheibenbogen, C., & Wirth, K. J. (2024). Key pathophysiological role of skeletal muscle disturbance. Journal of Cachexia, Sarcopenia and Muscle.
    https://doi.org/10.1002/jcsm.13669

    Role: Positions skeletal muscle as the dominant execution site of PEM downstream of vascular and ionic instability.

VIII. Foundational PEM Framing

18. Wirth, K., & Scheibenbogen, C. (2020). A unifying hypothesis of the pathophysiology of ME/CFS. Autoimmunity Reviews, 19(6), 102527.
    https://doi.org/10.1016/j.autrev.2020.102527

    Role: Foundational vascular–ionic framing of PEM; extended and closed into a self-sustaining recovery-failure loop in GLA v2.8.

IX. Downstream Amplifiers & Systemic Spread

(Expression, not persistence)

19. García-Cardeña, G., Martasek, P., Masters, B. S. S., Skidd, P. M., Couet, J., Li, S., Lisanti, M. P., & Sessa, W. C. (1997). Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Journal of Biological Chemistry, 272(41), 25437–25440.
    https://doi.org/10.1074/jbc.272.41.25437

    Role: Molecular basis for caveolin-mediated NO timing errors under membrane rigidity.

20. Nkiliza, A., Parks, M., Cseresznye, A., et al. (2021). Sex-specific plasma lipid profiles in ME/CFS. Journal of Translational Medicine, 19(1), 370.
    https://doi.org/10.1186/s12967-021-03035-6

    Role: Sex-biased lipid expression patterns reflecting downstream membrane and routing differences.

21. Paul, B. D., Lemle, M. D., Komaroff, A. L., & Snyder, S. H. (2021). Redox imbalance links COVID-19 and ME/CFS. PNAS, 118(34), e2024358118.
    https://doi.org/10.1073/pnas.2024358118

    Role: Supports redox involvement as a persistence amplifier, not a primary driver.

22. Missailidis, D., et al. (2025). Multi-omics identifies lipid accumulation and ether-phosphatidylcholine depletion. Journal of Translational Medicine, 23, 620.
    https://doi.org/10.1186/s12967-025-07620-x

    Role: Multi-omics evidence of membrane lipid remodeling under persistent stress.

23. Glass, K. A., Giloteaux, L., Zhang, S., & Hanson, M. R. (2025). Extracellular vesicle proteomics uncovers ER stress responses post-exercise. Clinical and Translational Medicine, 15, e70346.
    https://doi.org/10.1002/ctm2.70346

    Role: EV-mediated propagation of recovery-phase stress signals.

X. Systems-Level State Signatures

(Non-causal)

24. Xiong, R., Aiken, E., Caldwell, R., et al. (2025). AI-driven multi-omics modeling of ME/CFS. Nature Medicine, 31, 2991–3001.
    https://doi.org/10.1038/s41591-025-03788-3

    Role: Identifies reproducible disease states; predictive ≠ causal.

XI. SMPDL3B as a State-Dependent Biomarker

25. Rostami-Afshari, B., Elremaly, W., Franco, A., Elbakry, M. Y., Boufaied, I., … Moreau, A. (2025). SMPDL3B as a novel biomarker and therapeutic target in ME/CFS. Journal of Translational Medicine, 23(1), 748.
    https://doi.org/10.1186/s12967-025-06829-0

    Role: SMPDL3B reflects membrane state and termination pressure, not disease initiation.